Rhythm Pharmaceuticals, Inc.
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent…
Biotechnology
US, Boston [HQ]
Similar Stocks · Benchmarked Analysis · Peer Group
Peer Group Analysis
Similar Stocks · Benchmarked Analysis · Peer Group
Configuration
| Company | Price d* | Change d* | Volume, Avg. k, d* | Market Cap. d* | Revenue | Profit Net | Earnings | Free Cash Flow | Dividend Yield | P/E | EPS | Gross Margin % | Net Margin % | ROE % | ROA % | Quick Ratio % | Shares Outstanding d* | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biotechnology Average | - - | - - | - - | 13,187.27 | 864.59 | 209.92 | -152.79 | 36.14 | 0.00 | 20.9258 | -0.37 | -1.0751 | -24.2336 | -0.09 | -0.06 | 7.2289 | - - | ||
| Maximum | - - | - - | - - | 458,604.00 | 65,349.00 | 25,407.00 | 99,050.00 | 5,305.00 | 0.01 | 1,336.3467 | 6.70 | 3.0051 | 85.3485 | 0.38 | 8.35 | 61.5621 | - - | ||
| Minimum | - - | - - | - - | 0.00 | 0.00 | -1,175.00 | -56,335.00 | -1,185.00 | 0.00 | -164.8536 | -8.99 | -101.7758 | -1,444.7800 | -1.56 | -12.64 | 0.0007 | - - | ||
| Rocket Pharmaceuticals, Inc. RCKT | 13.98 | -0.84 -5.67% | 1,130 vs. 846 | 1,274.00 | 0.00 | -62.00 | -58.00 | -1,021.00 | -0.6600 | -10.0705 | 0.0000 | 0.0000 | 0.0000 | -0.1406 | -0.1242 | 10.2835 | 91.00 | ||
| Nuvalent, Inc. NUVL | 86.88 | -3.30 -3.66% | 772 vs. 521 | 6,064.00 | 0.00 | -44.00 | -36.00 | -330.00 | -0.6900 | -27.7942 | 0.0000 | 0.0000 | 0.0000 | -0.0659 | -0.0628 | 20.6970 | 69.00 | ||
| Rhythm Pharmaceuticals, Inc. RYTM | 56.23 | -3.54 -5.92% | 677 vs. 473 | 3,455.00 | 25.00 | -141.00 | -80.00 | -1,036.00 | -2.3500 | -4.5393 | 0.0000 | 0.8845 | -5.4443 | -2.2957 | -0.5466 | 3.9862 | 61.00 | ||
| Revolution Medicines, Inc. RVMD | 55.13 | -2.24 -3.90% | 1,944 vs. 1,156 | 9,273.00 | 0.00 | -116.00 | -163.00 | -1,253.00 | -0.7000 | -11.2467 | 0.0000 | 0.0000 | 0.0000 | -0.0672 | -0.0608 | 18.1763 | 168.00 | ||
| Akero Therapeutics, Inc. AKRO | 28.09 | -1.67 -5.61% | 1,079 vs. 524 | 1,960.00 | 0.00 | -53.00 | -35.00 | -627.00 | -0.9000 | -6.6902 | 0.0000 | 0.0000 | 0.0000 | -0.0630 | -0.0585 | 29.8643 | 69.00 | ||
| Arcellx, Inc. ACLX | 43.79 | 0.38 0.88% | 479 vs. 683 | 10,596.00 | 39.00 | -7.00 | -38.00 | -396.00 | -0.1400 | -122.7330 | 0.0000 | 0.9790 | -0.1834 | -0.0145 | -0.0092 | 5.3496 | 241.00 | ||
More Due Diligence
Leverage our visualization and data tables to compare over 25 years of financial data for AAPL and its peers.